Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

16.04USD
17 Feb 2017
Change (% chg)

$-0.18 (-1.11%)
Prev Close
$16.22
Open
$16.06
Day's High
$16.18
Day's Low
$15.82
Volume
1,954,603
Avg. Vol
2,865,237
52-wk High
$96.62
52-wk Low
$13.00

Latest Key Developments (Source: Significant Developments)

Perrigo company has filed an abbreviated new drug application with U.S. FDA for Clindamycin
Tuesday, 7 Feb 2017 08:09am EST 

Perrigo Company Plc : Has filed an abbreviated new drug application with U.S. Food and Drug Administration for Clindamycin . Notified Valeant Pharmaceuticals North America, Dow Pharmaceutical Sciences of its ANDA filing .On February 3, 2017, Valeant filed suit in United States District Court for district of New Jersey alleging patent infringement.  Full Article

Valeant Pharma reiterates its FY 2016 forecast
Tuesday, 10 Jan 2017 05:31pm EST 

Valeant Pharmaceuticals International Inc : Valeant Pharmaceuticals International Inc - Reiterating its full-year 2016 financial guidance, which was originally communicated in november 2016 . FY 2016 earnings per share view $5.43, revenue view $9.60 billion -- Thomson Reuters I/B/E/S Source: (http://bit.ly/2j2Tiup) Further company coverage: [VRX.TO] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Valeant Pharmaceuticals expands parameter range for Bausch+Lomb ultra for presbyopia contact lenses
Tuesday, 10 Jan 2017 06:00am EST 

Valeant Pharmaceuticals International Inc - :Expanded parameter range for Bausch + Lomb ultra for presbyopia contact lenses.  Full Article

Valeant to sell Dendreon to Sanpower Group for $819.9 mln in cash
Monday, 9 Jan 2017 10:40pm EST 

Valeant Pharmaceuticals International Inc : Valeant to sell Dendreon to Sanpower Group for $819.9 million in cash . Valeant Pharmaceuticals- co will use proceeds from sale of Dendreon to permanently repay term loan debt under its senior secured credit facility .Valeant Pharmaceuticals International-affiliate entered agreement to sell all outstanding equity interests in Dendreon Pharma to Sanpower Group.  Full Article

Valeant nears deal to sell Dendreon cancer business to Sanpower for more than $750 mln - CNBC
Monday, 9 Jan 2017 10:27pm EST 

: Valeant nears deal to sell dendreon cancer business to China's Sanpower for more than $750 million - CNBC, citing Dow Jones Further company coverage: [VRX.TO] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Orexigen therapeutics anticipates filing of new drug submission for Contrave
Thursday, 5 Jan 2017 07:50am EST 

Orexigen Therapeutics Inc :Anticipates filing of new drug submission for contrave with Health Canada by partner, Valeant Canada in Q1 2017.  Full Article

Valeant Pharmaceuticals International director Ross Thomas W. Sr. purchases 5,000 of co's shares
Friday, 16 Dec 2016 04:45pm EST 

Valeant Pharmaceuticals International Inc :Valeant Pharmaceuticals International director Ross Thomas W. Sr. Reports purchase of 5,000 shares of co's common stock on Dec 14 at $14.73 per share - sec filing.  Full Article

Pershing Square updates on sale of Valeant Pharmaceuticals shares by its onshore partnerships
Tuesday, 13 Dec 2016 04:28pm EST 

Valeant Pharmaceuticals International Inc : Pershing Square Capital Management says sold common stock of Valeant Pharmaceuticals International for accounts of PS and PS II, the two onshore partnerships . Pershing Square Capital Management - PS and PS II sold, respectively, 3.4 million shares and 117,512 shares of high-cost-basis common stock of valeant pharmaceuticals . Pershing Square says PS international and PSH, the two offshore funds, sold no shares of Valeant Pharmaceuticals' common stock . Pershing Square says in addition, it purchased to close, for the accounts of the Pershing Square funds, the $165.00 strike call options that the funds previously sold short in November 2015 . Pershing Square says the sale of Valeant stock was in order to generate a tax loss in 2016 for their investors .Pershing Square Capital Management reports it owns 7.8 percent stake in valeant pharmaceuticals international as of dec 12 - SEC filing.  Full Article

Valeant announces phase 3 results for psoriasis treatment IDP-118
Thursday, 8 Dec 2016 11:55am EST 

Valeant Pharmaceuticals International Inc : Valeant Pharmaceuticals announces phase 3 results for psoriasis treatment IDP-118 . Within phase 3 study of 215 adult subjects with moderate to severe psoriasis, IDP-118 showed statistical significance to vehicle .Expects to have data from a second confirmatory pivotal phase 3 study in 2017.  Full Article

Sirona Biochem says Wanbang Biopharma will formulate product in Jan 2017 to prepare for clinical trial
Thursday, 8 Dec 2016 08:00am EST 

Sirona Biochem Corp : Sirona Biochem Corp - "expect to receive one or more term sheets from interested parties before end of Q4 2016" for licensing agreement for TFC-1067 . Sirona Biochem Corp - Wanbang Biopharmaceuticals will formulate product (SGLT2 inhibitor) in January 2017 to prepare for a clinical trial . Sirona Biochem - Wanbang Biopharma will conduct additional pharmacology, toxicology study and file IND package with Chinese FDA for SGLT2 inhibitor .Sirona Biochem Corp - Valeant is aware of delays in scale-up and has not altered plans to commercialize skin lightener, TFC-849.  Full Article

More From Around the Web

Photo

FDA approves Valeant's drug to treat plaque psoriasis

The U.S. Food and Drug Administration on Wednesday approved Valeant Pharmaceuticals International Inc's Siliq to treat adults with moderate-to-severe plaque psoriasis.